Cancer
Malignant Rectal Neoplasm
CI-CAN-00008012Explore in graph →
Top-level388 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008012Explore in graph →
Clinical trials
1,551 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (153)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06459869 | NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer(FORTRESS) | active not recruiting | Phase 1 | 30 | Akamis BioINDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
| NCT02381561 | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04677413 | Ultra-fractionated Radiotherapy for Rectal Cancer | active not recruiting | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02403505 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer(CEA+RC-BCG) | active not recruiting | Phase 1 | 20 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04046445 | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer(KISIMA-01) | active not recruiting | Phase 1 | 96 | Amal TherapeuticsINDUSTRY | 4 | Jan 29, 2025 | clinicaltrials |
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials